The position of the target site for engineered nucleases improves the aberrant mRNA clearance in in vivo genome editing
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Yu, Sungsook | - |
dc.contributor.author | Nam, Tae Wook | - |
dc.contributor.author | Roh, Jae-il | - |
dc.contributor.author | Jin, Young | - |
dc.contributor.author | Han, Jeong Pil | - |
dc.contributor.author | Cha, Ji-Young | - |
dc.contributor.author | Kim, Yoon Ki | - |
dc.contributor.author | Yeom, Su-Cheong | - |
dc.contributor.author | Nam, Ki Taek | - |
dc.contributor.author | Lee, Han-Woong | - |
dc.date.accessioned | 2021-08-31T08:05:42Z | - |
dc.date.available | 2021-08-31T08:05:42Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-03-06 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57317 | - |
dc.description.abstract | Engineered nucleases are widely used for creating frameshift or nonsense mutations in the target genes to eliminate gene functions. The resulting mRNAs carrying premature termination codons can be eliminated by nonsense-mediated mRNA decay. However, it is unclear how effective this process would be in vivo. Here, we found that the nonsense-mediated decay was unable to remove the mutant mRNAs in twelve out of sixteen homozygous mutant mice with frameshift mutations generated using engineered nucleases, which is far beyond what we expected. The frameshift mutant proteins translated by a single nucleotide deletion within the coding region were also detected in the p53 mutant mice. Furthermore, we showed that targeting the exons present downstream of the exons with a start codon or distant from ATG is relatively effective for eliminating mutant mRNAs in vivo, whereas the exons with a start codon are targeted to express the mutant mRNAs. Of the sixteen mutant mice generated, only four mutant mice targeting the downstream exons exhibited over 80% clearance of mutant mRNAs. Since the abnormal products, either mutant RNAs or mutant proteins, expressed by the target alleles might obscure the outcome of genome editing, these findings will provide insights in the improved performance of engineered nucleases when they are applied in vivo. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | GENE KNOCKOUT | - |
dc.subject | DECAY | - |
dc.subject | RULES | - |
dc.subject | TALEN | - |
dc.subject | MICE | - |
dc.title | The position of the target site for engineered nucleases improves the aberrant mRNA clearance in in vivo genome editing | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Ki | - |
dc.identifier.doi | 10.1038/s41598-020-61154-4 | - |
dc.identifier.scopusid | 2-s2.0-85081257711 | - |
dc.identifier.wosid | 000560096000002 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.10, no.1 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | GENE KNOCKOUT | - |
dc.subject.keywordPlus | DECAY | - |
dc.subject.keywordPlus | RULES | - |
dc.subject.keywordPlus | TALEN | - |
dc.subject.keywordPlus | MICE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.